Scientific Abstracts
Background: Although medication of rheumatoid arthritis (RA) has been improved by early intensive treatment using csDMARDs, tsDMARDs and bDMARDs for decades, treatment of concomitant disease in RA patients, such as osteoporosis (OP), will be more important to improve activity of daily living of RA patients. Although denosumab (DMB), an anti-RANKL antibody, was approved for treatment of OP in Japan in 2013, clinical data in real world is lacking in patients with RA. We reported 12 months efficacy of denosumab on osteoporosis in patients with RA at EULAR 2016 in London 1) . Here we report results for 24 months. Objectives: To investigate the 24 months efficacy of denosumab (DMB) on osteoporosis in patients with rheumatoid arthritis (RA-OP) and to explore predictors of efficacy from multicenter study (TBCR-BONE). Methods: 59 female cases with RA-OP treated with DMB for 24 months were included in this study. Bone mineral density (BMD) of lumbar spine (LS-BMD) and total hip (TH-BMD) and serum bone turnover markers (P1NP and TRACP-5b) were measured at baseline and every 6 month until 24 months. Spearman's rank correlation coefficient was calculated between %increase of BMD at 24 months and various data (baseline patients' characteristics, parameters of RA disease activity [DAS28-CRP, SDAI, CRP, MMP-3] and bone turnover markers (BTMs) ). Time averaged data (ta-data) which was averaged data of every 6 month was utilized for analysis with respect to data of RA disease activity and BTMs besides baseline data. Results: Mean age was 59 years old. Mean RA duration was 16 years. Rates of concomitant prednisolone use was 33.9%. Mean DAS28-CRP was 2.7. 44% of cases had the past history of fracture. Mean FRAX was 28%. Daly teriparatide was used in 11 cases before DMB treatment. %increase of LSBMD at every 6 month was significantly increased (4.7%>6.7%>7.7%>8.3%) and %increase of THBMD at every 6 month was significantly increased (2.9%>3.3%>4.9%>4.9%) (Fig1). %decrease of P1NP and TRACP-5b was 37.4%>33.8%>25.5%>26.0% and 33.3%>29.8%>26.1%>23.1%, respectively (Fig2). Fig3 showed that parameters (correlation coefficient) which were correlated with %increase of LSBMD at 24 months were %increase of LSBMD at 6 months (0.61), baseline P1NP (0.33) and time averaged %decrease of TRACP-5b (0.30). Parameters (correlation coefficient) which were correlated with %increase of THBMD at 24 months were %increase of LSBMD at 6 months (0.42), %increase of THBMD at 6 months (0.69), baseline P1NP (0.36), time averaged %decrease of P1NP (0.37), baseline TRACP-5b (0.29) and time averaged %decrease of TRACP-5b (0.29). Although %increase of BMD at 24 months was not correlated with disease activity of RA, taCRP was significantly correlated with taP1NP (0.57) and taTRACP-5b (0.45). Background: The gout is an inflammatory multifactorial disorder where the diet, age, sex, absorption regulation of uric acid in kidney and genetic, contribute to the onset of the disease. The balance of uric acid concentration not only depends on metabolism of purines but also on the clearance of uric acid, in which many proteins participate in the reabsorption and transport of urate. Is unknown if the peripheral blood leukocyte cells can change their expression and regulation mechanism of the urate transporters by the presence of uric acid in gout patients [1] [2] [3] [4] . Objectives: Analyze changes in gene expression and the methylation pattern of the TLR2, TLR4, SLC2A9, SLC22A12, SLC22A3 and ABCG2 in neutrophils and peripheral blood monocytes from patients with gout and controls Methods: The isolation of peripheral blood neutrophils and monocytes cells was performed by negative immunomagnetic selection (MACxpress kit, EUA). By flow citometry were analyzed the previously separate cell populations, mononuclear (MN), polymorphonuclear (PMN) cells and neutrophils (N) (CD15, CD16, CD14). The DNA and RNA extraction was realized with a without columns kit and with Trizol technique. The gene expression analysis will be performed from total RNA by RT-PCR kit (Promega) . Methylation analysis will be carried out the bisulfite conversion (ABCAM) from total DNA and HRM-PCR. For both studies, gene expression and methylation analysis are designed specific primers Results: The biggest difference between asymptomatic gout patients (n=12) and controls (n=12), in the biochemical parameters (Table 1) , is in the higher levels of uric acid and triglycerides that the patient presents. Actually, we've already evaluated the genetic expression of TLR1, TLR2, TLR4 and IL1b in mononuclear cells of 5 asymptomatic gout patients and 5 controls (Plot 1). Interestingly, IL1b is UP-regulated in sample group bye a mean factor of 16.350 and TLR2 is UP-regulated in sample group in comparison to control group by a mean factor of 3.686. 
Conclusions

Conclusions:
The asymptomatic patients with a higher mean of uric acid (8mg/dL) and tryglicerides (145.60 mg/dL) had a higher expression of IL1b and TLR2 compared to controls.
